You are here

Shire Signs Deal to Develop a New Way to Administer Hemophilia Drug

New technology would allow oral dosing of drugs typically administered by injection

Shire PLC is partnering with a California-based company to develop a new way to administer a drug to treat hemophilia A, according to reporting by Reuters. The company, Rani Therapeutics, has developed a technology that will help oral delivery of peptides, proteins, and therapeutic antibodies that to date could be delivered only through injections.

Once delivered through Rani Pill—the oral delivery technology—the drug stays in the body until it enters the small intestine and the medicine is transferred into the intestinal wall, the companies said. The method does not expose the medication to digestive enzymes and is also expected to be pain free, since the intestines do not have sharp pain receptors, the companies said.

Shire, which made an equity investment in Rani, has the option to negotiate a licensing deal to develop and market the drug delivery approach, after completion of certain studies.

Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.

Source: Reuters; December 5, 2017.

More Headlines

Manufacturer used FDA’s 505(b)(2) abbreviated approval pathway
This is the first drug for patients with eosinophilic granulomatosis with polyangiitis
Industry will provide funding for programs in partnership with Addiction Policy Forum
Platform offers advanced technology to treat symptoms of Parkinson’s disease
Four in 10 remain in complete remission, updated data show
Patients with high PD-L1 level show benefit in first-line treatment
Pfizer launches generic to counteract Teva’s version
Tecentriq was combined with Avastin and chemotherapy as initial treatment